title: Gene therapy using adenovirus against malignant mesothelioma.
abstract: BACKGROUND
  Adenovirus vectors have been utilized for cancer gene therapies. The present study examined the oncolytic effects of adenovirus type 5 (Ad5) and fiber-substituted conditionally replicating adenovirus (CRAD) Ad5/F35 vectors on the human malignant mesothelioma cells MSTO-211H, NCI-H28, NCI-H2052, and NCI-H2452 cells.
  
  
  METHODS
  For the adenovirus, the first mRNA/protein to be made (~1 h after infection) is E1A. Ad5F35 and Ad5 CRAD vectors containing the E1 gene controlled by the human midkine promoter (Ad5F35/MKp-E1 and Ad5/MKp-E1, respectively) were constructed. Western blotting and cell viability assays were carried out in cells transfected with Ad5/MKp-E1 and Ad5F35/MKp-E1.
  
  
  RESULTS
  Coxsackie and adenovirus receptor (CAR), a cell surface target of Ad5, and CD46, a cell surface target of Ad35, were expressed in all the malignant mesothelioma cell lines examined here, as much as in HEK293 cells, with no significant differences in the expression levels among cells. Both Ad5/MKp-E1 and Ad5F35/MKp-E1 induced oncolysis of malignant mesothelioma cells in a viral particle-dependent manner, with similar efficacy.
  
  
  CONCLUSIONS
  The results of the present study suggest that both Ad5/MKp-E1 and Ad5F35/MKp-E1 are useful for the gene therapy of human malignant mesothelioma.
authors.affiliation: Laboratory of Cell and Gene Therapy Institute for Advanced Medical Sciences, Hyogo College of Medicine, Nishinomiya, Japan.
authors.forename: Akinobu
authors.initials: A
authors.lastname: Gotoh
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kanno
authors.forename: Hisao
authors.initials: H
authors.lastname: Nagaya
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
authors.forename: Chiharu
authors.initials: C
authors.lastname: Tabata
authors.forename: Kazuya
authors.initials: K
authors.lastname: Fukuoka
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tagawa
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Nishizaki
mesh_terms: D017498:Adenovirus E1 Proteins / Q000235:genetics; D000260:Adenoviruses, Human / Q000235:genetics / Q000502:physiology*; D045744:Cell Line, Tumor; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein / Q000096:biosynthesis; D015316:Genetic Therapy / Q000379:methods*; D057809:HEK293 Cells; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000628:therapy* / Q000821:virology; D051916:Membrane Cofactor Protein / Q000096:biosynthesis; D008654:Mesothelioma / Q000235:genetics* / Q000628:therapy* / Q000821:virology; D000086002:Mesothelioma, Malignant; D000078792:Midkine; D009414:Nerve Growth Factors / Q000235:genetics; D050130:Oncolytic Virotherapy / Q000379:methods*; D011401:Promoter Regions, Genetic; D014162:Transfection; D014779:Virus Replication
chemical_list: D017498:Adenovirus E1 Proteins; C497857:CD46 protein, human; C568771:CLMP protein, human; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; C066254:MDK protein, human; D051916:Membrane Cofactor Protein; D009414:Nerve Growth Factors; D000078792:Midkine